Indication
EXPAREL is indicated for administration into the surgical site to produce postsurgical analgesia.

Available in a 133 mg/10 mL Dose for Small Surgical Procedures
To better serve the needs of your patients, Pacira Pharmaceuticals, Inc. is offering a 133 mg/10 mL dose of EXPAREL. The 133 mg/10 mL dose is half the dose and half the volume of the 266 mg/20 mL dose and is intended for small surgical procedures where 20 mL of volume will not fit into the surgical site.

Greater flexibility for more surgical procedures
The lower 133 mg/10 mL dose is sufficient to provide long-lasting postsurgical analgesia in small surgical sites relative to the size and depth of a bunionectomy, third molar extraction, hand and wrist procedure, or small facial plastic procedure.*

The 266 mg/20 mL dose is the appropriate dose to utilize in larger surgical procedures that require a higher dose and volume to provide effective postsurgical pain control.

Available in cartons of 4 and 10 vials
The 133 mg/10 mL and 266 mg/20 mL doses of EXPAREL are available in cartons of 4 and 10 vials.
As of March 20, 2017, there are 4 SKUs of EXPAREL available.

<table>
<thead>
<tr>
<th>NDC #</th>
<th>Dose/Vial Size</th>
<th>Configuration</th>
</tr>
</thead>
<tbody>
<tr>
<td>65250-266-09</td>
<td>EXPAREL 266 mg/20 mL</td>
<td>Carton of 10 vials</td>
</tr>
<tr>
<td>65250-266-04</td>
<td>EXPAREL 266 mg/20 mL</td>
<td>Carton of 4 vials</td>
</tr>
<tr>
<td>65250-133-09</td>
<td>EXPAREL 133 mg/10 mL</td>
<td>Carton of 10 vials</td>
</tr>
<tr>
<td>65250-133-04</td>
<td>EXPAREL 133 mg/10 mL</td>
<td>Carton of 4 vials</td>
</tr>
</tbody>
</table>

If you have any questions, please contact your Pacira Surgical Account Specialist or call 1-855-RX-EXPAREL (793-9727).

*These are examples of procedures that typically require the above-referenced dose of EXPAREL. Please use your professional judgment when determining the appropriate dose of EXPAREL for a given surgical procedure, and refer to the full Prescribing Information before using EXPAREL.

Please see Important Safety Information on reverse side.
Full Prescribing information is available at www.EXPAREL.com.
Indication
EXPAREL is indicated for administration into the surgical site to produce postsurgical analgesia.

Important Safety Information
• EXPAREL is contraindicated in obstetrical paracervical block anesthesia
• In clinical trials, the most common adverse reactions (incidence ≥10%) following EXPAREL administration were nausea, constipation, and vomiting
• EXPAREL is not recommended to be used in the following patient population: patients <18 years old and/or pregnant patients
• Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations

Warnings and Precautions Specific to EXPAREL
• EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks, or intravascular or intra-articular use
• Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Formulations of bupivacaine other than EXPAREL should not be administered within 96 hours following administration of EXPAREL

Warnings and Precautions for Bupivacaine-Containing Products
• Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesias. CNS reactions are characterized by excitation and/or depression
• Cardiovascular System Reactions: Toxic blood concentrations depress cardiac conductivity and excitability which may lead to dysrhythmias sometimes leading to death
• Allergic Reactions: Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients
• Chondrolysis: There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use

Full Prescribing information is available at www.EXPAREL.com.